Global Hyperoxaluria (IV, IM, S/C, Oral) Pipeline Analysis Report 2018 - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Hyperoxaluria Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments” report has been added to ResearchAndMarkets.com’s offering.

This report covers 6 drugs currently in different phases of development.

The report provides Hyperoxaluria treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.

Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.


By Company

By Phase

NDA Filed Phase III Phase II Phase I Pre-clinical Discovery

By Molecule Type

Small Molecules Biologics Peptides or Small proteins

By Region

North America South America Europe Middle East and Africa Asia Pacific

By Route of Administration

IV IM S/C Oral

Key Topics Covered

1. Introduction

1.1. Research Methodology

1.2. Research Scope

2. Disease Overview

3. Executive Summary

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company

5.2. Analysis by Phase

Drug Name Generic Name Synonyms Company Collaborator Route of Administration Target Mechanism of Action Technology Molecule Type CAS Number Weight Chemical Formula IUPAC Name ATC Code

5.3. By Molecule Type

5.4. Analysis by Region

6. Company Profiling

6.1. Allena Pharmaceuticals Inc.

6.2. Alnylam Pharmaceuticals Inc.

6.3. Captozyme

6.4. Dicerna Pharmaceuticals Inc.

6.5. Intellia Therapeutics Inc.

6.6. OxThera

For more information about this report visit https://www.researchandmarkets.com/research/8hqxlw/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605005862/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials,Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 06:52 AM/DISC: 06/05/2018 06:52 AM


Update hourly